Cayuga Marketing Seeks to Gain Share in Global Dairy Market by Herrling, Joel M.
Dairy farmers in the Finger Lakes of upstate New 
York are joining the ranks of the region’s agricul-
tural products innovators. The region features winer-
ies where grapes are fermented into award-winning 
wines that are as good, if not better, than their 
worldwide competitors, to farmers who have created 
a niche for products made from Alpaca wool.  
Dairy farmers of this region are continuously 
developing new ideas for their milk. They are inno-
vative, dedicated and progressive dairy business 
people. One such inspiring group is Cayuga Milk 
Ingredients, LLC (CMI), which was created on April 
24th, 2012 by the collective efforts of the Board of 
Managers of Cayuga Marketing, LLC and present 
CEO Kevin Ellis. CMI is comprised of 21 family-
owned farms that milk approximately 31,000 cows 
and employ 600+ workers within the Finger Lakes 
region. All of the participating farms are located 
within 40 miles of the City of Auburn. 
“The vision truly came from the farmers and the 
board members who put forth significant time and 
effort to research the many different product mix 
and potential partnership options,” Ellis said. He was 
responsible for a high percentage of the leg work 
and analysis. “Every member has given insight from 
their own unique perspectives for the vision and 
strategy behind this endeavor.”
Before the first shovel broke ground on the new 
milk processing plant, the members of Cayuga 
Marketing marketed and continue to market raw 
fluid milk through Dairylea Cooperative in Syracuse, 
NY. Board members strongly feel that this has been 
a very beneficial relationship for over 12 years. But 
the dramatic increase in fuel costs, up 230% from 
2000 levels, along with the Federal Order price dif-
ferentials remaining almost unchanged, has resulted 
in lower profitability for farmers. This was the major 
catalyst for the group’s focus. 
“The board of Cayuga Marketing decided it was 
in their best long-term interest to have a milk plant 
in close proximity to the farms in an effort to reduce 
milk miles and transportation costs,” Ellis said. 
CMI is developing an approximate 25 acre site at 
the Cayuga County Industrial Development Agency 
(CCIDA) Industrial Park, adjacent to the City of 
Auburn, and located in the Cayuga County Town 
of Aurelius. Plant construction officially started in 
October of 2012, and is expected to be completed 
by July 2014. The state of the art new facility will 
produce milk protein concentrates and isolates, milk 
powders, milk powder blends for the global food and 
nutrition industries, liquid cream, and milk permeate 
products.
The completion of the 108,000+/- sq. ft. manu-
facturing facility will ultimately lead to numerous 
benefits for its members/owners. The primary one 
is short milk hauls and control over milk receiving. 
This will enable multiple loads per truck per day.
ISSUES AND PERSPECTIVES By Joel M. Herrling
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QJoel M. Herrling is Quality Assurance Supervisor 
with Cayuga Milk Ingredients, LLC. He can be 
reached by email at jherrling@cmingredients.com or 
by phone at 315.246.1654.
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For subcutaneous injection in the posterior aspect of the ear where it attaches 
to the head (base of the ear) in lactating dairy cattle. For subcutaneous injection 
in the middle third of the posterior aspect of the ear or in the posterior aspect of 
the ear where it attaches to the head (base of the ear) in beef and non-lactating 
dairy cattle. Not for use in calves to be processed for veal.
CAUTION
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
INDICATIONS
EXCEDE Sterile Suspension is indicated for treatment of bovine respiratory disease 
(BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, 
Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and 
lactating dairy cattle.
EXCEDE Sterile Suspension is also indicated for the control of respiratory disease 
in beef and non-lactating dairy cattle which are at high risk of developing BRD 
associated with M. haemolytica, P. multocida, and H. somni.
EXCEDE Sterile Suspension is also indicated for the treatment of bovine foot rot 
(interdigital necrobacillosis) associated with Fusobacterium necrophorum and 
Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.
EXCEDE Sterile Suspension is also indicated for treatment of acute metritis (0-10 
days postpartum) associated with bacterial organisms susceptible to ceftiofur in 
lactating dairy cattle.
CONTRAINDICATIONS
As with all drugs, the use of EXCEDE Sterile Suspension is contraindicated in 
animals pre viously found to be hypersensitive to the drug.
WARNINGS
FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. 
Topical exposures to such antimicrobials, including ceftiofur, may elicit mild to 
severe allergic reactions in some individuals. Repeated or prolonged exposure may 
lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth 
and clothing. Sensitization of the skin may be avoided by wearing protective gloves.
Persons with a known hypersensitivity to penicillin or cephalosporins should avoid 
exposure to this product.
In case of accidental eye exposure, flush with water for 15 minutes. In case of 
accidental skin exposure, wash with soap and water. Remove contaminated 
clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek 
medical attention.
The material safety data sheet contains more detailed occupational safety 
information. To obtain a material safety data sheet please call 1-800-733-5500. 
To report any adverse event please call 1-800-366-5288.
Intra-arterial injection may occur during administration of EXCEDE Sterile 
Suspension via middle third of the ear injection or base of the ear injection directed 
toward the opposite eye. Intra-arterial injection of EXCEDE Sterile Suspension is 
likely to result in sudden death of the animal.
RESIDUE WARNINGS
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13-day pre-slaughter withdrawal period is required after the last 
treatment.
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Following subcutaneous injection in the middle third of the posterior aspect of the 
ear, thickening and swelling (characterized by aseptic cellular infiltrate) of the ear 
may occur. As with other parenteral injections, localized post-injection bacterial 
infections may result in abscess formation. Attention to hygienic procedures can 
minimize their occurrence.
Following injection at the posterior aspect of the ear where it attaches to the head 
(base of the ear), areas of discoloration and signs of inflammation may persist at 
least 13 days post administration resulting in trim loss of edible tissue at slaughter. 
Injection of volumes greater than 20 mL, in the middle third of the ear, may result 
in open draining lesions in a small percentage of cattle. 
The effects of ceftiofur on bovine reproductive performance, pregnancy, and 
lactation have not been determined.
ADVERSE EFFECTS
Intra-arterial injection may occur during administration of EXCEDE Sterile 
Suspension via middle third of the ear injection or base of the ear injection directed 
toward the opposite eye. Intra-arterial injection of EXCEDE Sterile Suspension is 
likely to result in sudden death of the animal. During the conduct of clinical studies, 
there was a low incidence of acute death (see ANIMAL SAFETY) confirmed to be the 
result of inadvertent intra-arterial injection. No other adverse systemic effects were 
noted for either the antibiotic or formulation during any of the clinical and target 
animal safety studies.
STORAGE CONDITIONS
Store at controlled room temperature 20° to 25°C (68° to 77°F). Shake well before 
using.  Contents should be used within 12 weeks after the first dose is removed.
HOW SUPPLIED
EXCEDE Sterile Suspension is available in the following package sizes:
100 mL vial
250 mL vial
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 “The issue we face today is that many 
milk plants only operate their receiving bays 
for one shift, which decreases the amount 
of truck turns. This increases the number 
of trucks and trailers needed to get milk to 
these plants,” Ellis said. 
Other excellent benefits include: possible 
use of renewable energy in its processes, 
efficiencies from a new plant, opportunities to 
differentiate the milk supply, creating another 
viable long-term market for New York milk 
and the initial creation of an estimated 55 
local jobs. Ultimately the plant will reduce 
operating costs to the farmers and add value 
to their raw milk, which will be sold at a pre-
mium domestically and internationally.
The members of the Cayuga Marketing 
board explored many different values and 
strategies for their milk, such as fluid milk, 
liquid UF, various cheeses, casein and 
caseinates. Due to the constraints of limited 
capital, a long distance from metro markets, 
and no retail or brand marketing experience, 
the clear choice was made to market a com-
modity product. 
The plant will need to utilize a majority 
of the milk supply to reap trucking saving 
for the farmers, while also being appropri-
ately sized to achieve a competitive econo-
my of scale compared with competitors. The 
market for products needs to be sizable and 
growing to limit market risk for the farmers.
“Bottom Line:  We discovered that the 
world market for 
dairy powders 
and proteins 
was huge and 
growing rapidly, 
mostly driven 
by the rising 
wealth in coun-
tries like China,” 
Ellis said. 
“Additionally, 
we found a part-
ner willing to 
provide us with 
their state of the 
art technology.”
The project 
will allow for the use of current and future 
technology, while also hopefully encourag-
ing collaboration with food scientists at 
Cornell University, for research and devel-
opment of new products and student educa-
tion.
While erection of the building is still 
underway, the vision of CMI is to be a 
respected and trusted global source of the 
highest quality dairy ingredients. As with 
most successful companies, CMI will be 
employee and customer centric, in an effort 
to build a profitable dairy company that will 
sustain their farmers and employees for gen-
erations to come. 
“We desire to be an employer of choice 
in the region and will do so by creating a 
work environment where employees are 
welcomed, challenged, supported, and know 
that their contributions are making a differ-
ence,” Ellis said. He is enthusiastic about 
the intelligent, hard-working and motivated 
employees already on staff.  “This core 
group of exemplary employees will become 
our most fierce competitive advantage.”
These local farmers and owners are utiliz-
ing local talent, who will retain their profits 
in the local community. CMI has a long list 
of goals to obtain, with the most important 
one being to utilize all of the milk from 
Cayuga County farms, which in turn will 
allow for growth in the future, and eventu-
ally incorporate the ability to balance the 
member’s milk supply. CMI will encourage 
and pay for the highest quality milk from its 
members. S
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